Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
Farkouh ME, Verheugt FW, Ruland S, Kirshner H, Jeger R, Gitton X, Krammer G, Stricker K, Sallstig P, Mellein B, Matchaba P, Chesebro JH. Farkouh ME, et al. Among authors: sallstig p. J Clin Hypertens (Greenwich). 2008 Aug;10(8):592-602. doi: 10.1111/j.1751-7176.2008.07802.x. J Clin Hypertens (Greenwich). 2008. PMID: 18772641 Free PMC article. Clinical Trial.
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A. Schlesinger N, et al. Among authors: sallstig p. Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3. Ann Rheum Dis. 2011. PMID: 21540198 Free PMC article. Clinical Trial.
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY. Fleischmann R, et al. Among authors: sallstig p. BMC Musculoskelet Disord. 2008 Mar 7;9:32. doi: 10.1186/1471-2474-9-32. BMC Musculoskelet Disord. 2008. PMID: 18328090 Free PMC article. Clinical Trial.
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.
Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, So A. Schlesinger N, et al. Among authors: sallstig p. Arthritis Res Ther. 2011 Mar 25;13(2):R53. doi: 10.1186/ar3297. Arthritis Res Ther. 2011. PMID: 21439048 Free PMC article. Clinical Trial.